US 9,435,813 B2 · Biomarkers of hemorrhagic shock

Abstract

Methods for the use of keratinocyte chemoattractant (KC)/human growth-regulated oncogene (GRO) (KC/GRO), apolipoprotein A2 (APOA2), angiotensinogen r (AGT), thyroglobulin (TG), disintegrin and metalloproteinase domain-containing protein 17 (ADAM17), anionic trypsin-1 (PRSS1), complement C4 (C4A), zona pellucida sperm-binding protein 1 (ZP1), neuropilin-2 (NRP2), solute carrier family 13 member 2 (SLC13A2), glucagon-like peptide 2 receptor (GLP2R), lipoma high mobility group protein isoform I-C (HMGIC) fusion partner-like protein 4 (LHFPL4), and claudin-3 (CLDN3) as biomarkers for diagnosis and prognosis, and for monitoring the efficacy of treatment, in hemorrhagic shock (HS).

Claims25

Dependent claims

A method of predicting and improving prognosis of a subject suffering from hemorrhagic shock (HS), the method comprising:

obtaining a sample comprising serum from the subject;
determining expression levels of keratinocyte chemoattractant (KC)/human growth-regulated oncogene (GRO) (KC/GRO), zona pellucida sperm-binding protein 1 (ZP1), and apolipoprotein A2 (APOA2) in the sample to obtain test values;
comparing the test values to respective reference values that represent threshold levels of KC/GRO, ZP1, and APOA2;
identifying the subject as having an increased risk of mortality due to HS if the test values are above the reference values, or identifying the subject as having an increased chance of survival if the test values are below the reference values, and
administering an effective amount of a vasopressor to the subject identified as having an increased risk of mortality due to HS, thereby improving prognosis of the subject.

2 more elements

A method of predicting and improving prognosis of a subject suffering from HS, the method comprising:

obtaining a sample comprising serum from the subject;
determining expression levels of KC/GRO, ZP1, and APOA2 in the sample to obtain test values;
comparing the test values to respective reference values that represent threshold levels of KC/GRO, ZP1, and APOA2;
identifying the subject as having an increased risk of mortality due to HS if the test values are above the reference values, or identifying the subject as having an increased chance of survival if the test values are below the reference values;
and
administering an effective amount of a histone deacetylase 1 (HDAC1) inhibitor to the subject identified as having an increased risk of mortality due to HS, thereby improving prognosis of the subject.

3 more elements

A method of predicting and improving prognosis of a subject suffering from HS, the method comprising:

obtaining a sample comprising serum from the subject;
determining expression levels of KC/GRO, ZP1, and APOA2 in the sample to obtain test values;
comparing the test values to respective reference values that represent threshold levels of KC/GRO, ZP1, and APOA2;
identifying the subject as having an increased risk of mortality due to HS if the test values are above the reference values, or identifying the subject as having an increased chance of survival if the test values are below the reference values;
and
administering a treatment for HS to the subject identified as having an increased risk of mortality due to HS, wherein the treatment comprises fluid resuscitation or transfusion of blood or a blood product, thereby improving prognosis of the subject.

3 more elements

Dependencies are inferred from the claim text.

Biomarkers of hemorrhagic shock

Life of this patent

Biomarkers of hemorrhagic shock

Life of this patent

Abstract

Claims25